Last Updated on October 17, 2024 by The Health Master
Gland Pharma Limited, a generic injectable focused pharmaceutical company, received tentative approval from the United States Food and Drug Administration (USFDA) for sugammadex injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial
This injection is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Bridion injection, 100 mg/mL, of Merck Sharp & Dohme Corp. (Merck Sharp & Dohme).
Sugammadex injection is used to reverse the effects of the muscle relaxants rocuronium bromide and vecuronium bromide given to patients during surgery.
Gland Pharma will launch the product through its marketing partner on receipt of final approval.
The sugammadex injection, 200 mg/2 mL and 500 mg/5 mL single-dose vial has US sales of approximately US$615 million for twelve months ending in April 2021, according to IQVIA.
USFDA gives nod to Drug to treat Rare Autoimmune Disease
USFDA gives tentative nod to Lupin for generic Brexpiprazole tablets
Zydus Cadila gets USFDA nod for drug to treat Psoriasis
Zydus Cadila gets USFDA nod for Antidepressant drug
Zydus Cadila gets tentative nod from USFDA for Brexpiprazole tablets
USFDA to review use of Blood Disorder Therapy in children
Recommendation of restriction on import of IPA used by Pharma Industry
Licensing process to ASU drug manufacturers made Paperless
Dedicated chapter on Medical Devices should be included in Pharmacy Course:…
Generic medicines are cheaper as compared to branded and equally effective
USFDA gives nod to Drug to treat Rare Autoimmune Disease
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
